Curcumin Supplementation and Patients With Type 2 Diabetes

Non Insulin Dependent Diabetes Clinical Trial

Official title:

The Effect of Curcumin Supplementation on Anthropometric Indices, Insulin Resistance and Oxidative Stress in Patients With Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02529982
• Other study ID #: 1370
• Status: Completed
• Phase: N/A
• Start date: July 2015
• Est. completion date: April 2016

Study information

• Verified date: February 2019
• Source: National Nutrition and Food Technology Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Diabetes mellitus is the most common endocrine disorder, causes many complications such as micro- and macro-vascular diseases. Various kinds of antidiabetic drugs have been developed, but most of them have side effects. Recently, the use of natural plant products has gained more attention among scientists in order to prevent diabetic vascular complications. Curcumin is a natural yellow product derived from the turmeric rhizome which has shown to be non-toxic and exhibits various bio¬logical activities such as anti-oxidant, anti-inflammatory, anti-carcinogenic, and anti-diabetic effects. Curcumin is effective in reducing glycemic index and hyperlipidemia in rodent models and is relatively inexpensive and safe. Most of the studies conducted on animal model, and just a few of them are on human model. The present study was planned to evaluate the effects of curcumin supplementation The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: April 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 65 Years

Eligibility

insulin Inclusion Criteria:

• a) Tendency to participate b) Age range of 40-65 c) Suffering from diabetes type 2 ( between 1 to 10 yeares) d) BMI 18/5-30 e) Patients with diabetes who administer oral hypoglycemic agents and do not use

Exclusion Criteria:

• a) patients with liver diseases b) patients with kidney diseases c) patients with inflammatory diseases d) patients with liver diseases e) Administering herbal agents f) Administering multivitamins and minerals in past 3 months

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Non Insulin Dependent Diabetes

Intervention

Dietary Supplement:
• Curcumin

• Placebo

Locations

Country	Name	City	State
Iran, Islamic Republic of	NNFTRI clinic	Tehran

Sponsors (1)

Lead Sponsor	Collaborator
National Nutrition and Food Technology Institute

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	fasting blood sugar		10 weeks
Primary	Insulin		10 week
Primary	HbA1c		10 week
Primary	Homeostatic Model Assessment of Insulin Resistance		10 week
Primary	Change in pancreatic B-cell function		10 week
Secondary	total capacity antioxidant		10 weeks
Secondary	Malondialdehyde		10 week
Secondary	Body mass index		10 week
Secondary	Waist circumference		10 week